Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Guselkumab in Palmoplantar Pustulosis
jRCT2080223067Phase 3
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in Palmoplantar Pustular Psoriasis (PPPP) (4 arms), sponsored by Janssen Pharmaceutical.
02
Drugs
guselkumab
03
Conditions
Palmoplantar Pustular Psoriasis (PPPP)
Beyond the preview
Go deeper on jRCT2080223067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223067.